Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment ...

People who receive stem cell therapy within a week of their first heart attack have nearly a 60 per cent lower risk of ...

When Lee woke one morning in 2008, a deep, unshakeable ache pinned her to the bed. She hadn't exercised, partied, or touched ...

Fueled by a handful of trials and word-of-mouth buzz, low-dose naltrexone is gaining momentum among patients and some doctors as an off-label treatment for chronic pain.

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights a pair of “timely and cool” stories on point-of-care AI use and the FDA approval of ...

Results of a systematic review and meta-analysis showed that LDN was safe and effective for reducing pain and improving ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman, M.D., Chief Executive Officer ...

Tonix Pharmaceuticals (TNXP) presented data on Tonmya, which was investigated as TNX-102 SL, at the 2025 American College of Rheumatology ...

Fibromyalgia, which causes chronic pain all over the body, is poorly understood, but two studies – made up of millions of ...

Tonix Pharmaceuticals plans a 4Q25 Tonmya launch for fibromyalgia with strong cash and premium pricing targeting a large ...